Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy

Sara Kathleen Powell, Ricardo Rivera-Soto, Steven J. Gray

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Over the last five years, the number of clinical trials involving AAV (adeno-associated virus) and lentiviral vectors continue to increase by about 150 trials each year. For continued success, AAV and lentiviral expression cassettes need to be designed to meet each disease's specific needs. This review discusses how viral vector expression cassettes can be engineered with elements to enhance target specificity and increase transgene expression. The key differences relating to target specificity between ubiquitous and tissue-specific promoters are discussed, as well as how endogenous miRNAs and their target sequences have been used to restrict transgene expression. Specifically, relevant studies indicating how cis-acting elements such as introns, WPRE, polyadenylation signals, and the CMV enhancer are highlighted to show their utility for enhancing transgene expression in gene therapy applications. All discussion bears in mind that expression cassettes have space constraints. In conclusion, this review can serve as a menu of vector genome design elements and their cost in terms of space to thoughtfully engineer viral vectors for gene therapy.

Original languageEnglish (US)
Pages (from-to)49-57
Number of pages9
JournalDiscovery medicine
Volume19
Issue number102
StatePublished - Jan 1 2015

Fingerprint

Transgenes
Genetic Therapy
Dependovirus
Polyadenylation
Viral Genes
MicroRNAs
Introns
Clinical Trials
Genome
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. / Powell, Sara Kathleen; Rivera-Soto, Ricardo; Gray, Steven J.

In: Discovery medicine, Vol. 19, No. 102, 01.01.2015, p. 49-57.

Research output: Contribution to journalArticle

@article{1f8e5173bc8548ec957935cca7e109b0,
title = "Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy",
abstract = "Over the last five years, the number of clinical trials involving AAV (adeno-associated virus) and lentiviral vectors continue to increase by about 150 trials each year. For continued success, AAV and lentiviral expression cassettes need to be designed to meet each disease's specific needs. This review discusses how viral vector expression cassettes can be engineered with elements to enhance target specificity and increase transgene expression. The key differences relating to target specificity between ubiquitous and tissue-specific promoters are discussed, as well as how endogenous miRNAs and their target sequences have been used to restrict transgene expression. Specifically, relevant studies indicating how cis-acting elements such as introns, WPRE, polyadenylation signals, and the CMV enhancer are highlighted to show their utility for enhancing transgene expression in gene therapy applications. All discussion bears in mind that expression cassettes have space constraints. In conclusion, this review can serve as a menu of vector genome design elements and their cost in terms of space to thoughtfully engineer viral vectors for gene therapy.",
author = "Powell, {Sara Kathleen} and Ricardo Rivera-Soto and Gray, {Steven J.}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "19",
pages = "49--57",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "102",

}

TY - JOUR

T1 - Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy

AU - Powell, Sara Kathleen

AU - Rivera-Soto, Ricardo

AU - Gray, Steven J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Over the last five years, the number of clinical trials involving AAV (adeno-associated virus) and lentiviral vectors continue to increase by about 150 trials each year. For continued success, AAV and lentiviral expression cassettes need to be designed to meet each disease's specific needs. This review discusses how viral vector expression cassettes can be engineered with elements to enhance target specificity and increase transgene expression. The key differences relating to target specificity between ubiquitous and tissue-specific promoters are discussed, as well as how endogenous miRNAs and their target sequences have been used to restrict transgene expression. Specifically, relevant studies indicating how cis-acting elements such as introns, WPRE, polyadenylation signals, and the CMV enhancer are highlighted to show their utility for enhancing transgene expression in gene therapy applications. All discussion bears in mind that expression cassettes have space constraints. In conclusion, this review can serve as a menu of vector genome design elements and their cost in terms of space to thoughtfully engineer viral vectors for gene therapy.

AB - Over the last five years, the number of clinical trials involving AAV (adeno-associated virus) and lentiviral vectors continue to increase by about 150 trials each year. For continued success, AAV and lentiviral expression cassettes need to be designed to meet each disease's specific needs. This review discusses how viral vector expression cassettes can be engineered with elements to enhance target specificity and increase transgene expression. The key differences relating to target specificity between ubiquitous and tissue-specific promoters are discussed, as well as how endogenous miRNAs and their target sequences have been used to restrict transgene expression. Specifically, relevant studies indicating how cis-acting elements such as introns, WPRE, polyadenylation signals, and the CMV enhancer are highlighted to show their utility for enhancing transgene expression in gene therapy applications. All discussion bears in mind that expression cassettes have space constraints. In conclusion, this review can serve as a menu of vector genome design elements and their cost in terms of space to thoughtfully engineer viral vectors for gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=84940564728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940564728&partnerID=8YFLogxK

M3 - Article

C2 - 25636961

AN - SCOPUS:84940564728

VL - 19

SP - 49

EP - 57

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 102

ER -